Notably Chk1 inhibitors have been developed that appear to enhance the toxicity of DNA damaging agents in p53 deficient tumour cells but not p53-proficient cells [38] offering prospects for the targeted activation of the Chk1-suppressed apoptotic pathway in at least some types of tumour cells. Here, TP53 is linked to neoplasm.